1. Volume 136, Issue 1, Pages 138-148 (January 2009)
Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C- Related Advanced Liver Disease 
Anna S. Lok, Leonard B. Seeff, Timothy R. Morgan, Adrian M. di Bisceglie, Richard K. Sterling, Teresa M. Curto, Gregory T. Everson, Karen L. Lindsay, William M. Lee, Herbert L. Bonkovsky, Jules L. Dienstag, Marc G. Ghany, Chihiro Morishima, Zachary D. Goodman 
Gastroenterology 
Volume 136, Issue 1, Pages (January 2009)
DOI: /j.gastro
Copyright © 2009 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier estimates of cumulative incidence of HCC (A) among patients randomized to maintenance peginterferon treatment or control and (B) among patients with bridging fibrosis (Ishak score 3 or 4) vs cirrhosis (Ishak score 5 or 6) on baseline biopsy. Cases diagnosed within 12 months of enrollment were presumed to have been present at the time of enrollment and were excluded. One patient in the treatment group met criteria for HCC 11 months after randomization. This patient relapsed after 48 weeks of Lead-in treatment and had been in the study for 16 months at the time of randomization.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

3. Figure 2
Kaplan–Meier estimates of cumulative incidence of HCC among patients predicted to have low, intermediate, and high risk of HCC according to regression model IV.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions

4. Figure 3
Kaplan–Meier estimates of cumulative incidence of HCC (A) in patients with and without esophageal varices or cirrhosis and (B) in patients with baseline platelet (Plt) count <100, 100–149, and ≥150 × 1000/mm3.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2009 AGA Institute Terms and Conditions